ALMS Latest Headlines

This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

at www.benzinga.com (Wed, 21-Jan 8:49 AM)

Alumis Inc. (ALMS) Receives a Buy from Chardan Capital

at www.tipranks.com (Wed, 21-Jan 3:35 AM)

Alumis Secures $300 Million in Upsized Public Offering—What Does This Mean for Its Immunology Pipeline?

Market Chameleon (Thu, 8-Jan 7:53 AM)

Alumis Launches $175M Public Offering: What Does the Move Signal for Investors?

Market Chameleon (Wed, 7-Jan 10:34 AM)

Alumis Announces Phase 3 ONWARD Topline Data Call—Key Catalysts Ahead for Psoriasis Treatment Pipeline

Market Chameleon (Tue, 6-Jan 9:52 AM)

Alumis' Envudeucitinib Achieves Top Results in Phase 3 Trials: Over 65% of Psoriasis Patients Attain Near-Complete Skin Clearance

Market Chameleon (Tue, 6-Jan 7:06 AM)